← Back to Screener
Merck & Co., Inc. (MRK)
Price$117.10
Favorite Metrics
Price vs S&P 500 (26W)29.72%
Price vs S&P 500 (4W)-5.21%
Market Capitalization$293.13B
P/E Ratio (Annual)16.06x
Indicated Dividend Yield (Annual)2.86%
All Metrics
P/CF (Annual)17.80x
Book Value / Share (Quarterly)$21.26
P/TBV (Annual)10.08x
Indicated Dividend (Annual)$3.24
Revenue Growth (3Y)3.12%
Cash Flow / Share (Quarterly)$4.99
Payout Ratio (TTM)44.79%
Price vs S&P 500 (YTD)8.98%
Gross Margin (TTM)78.55%
Net Profit Margin (TTM)28.08%
EPS (TTM)$7.28
10-Day Avg Trading Volume9.80M
EPS Excl Extra (TTM)$7.28
Revenue Growth (5Y)9.38%
EPS (Annual)$7.28
Dividend / Share (Annual)$3.27
ROI (Annual)17.91%
Gross Margin (Annual)81.50%
Net Profit Margin (5Y Avg)21.33%
Cash / Share (Quarterly)$5.89
P/E Basic Excl Extra (TTM)16.06x
Revenue Growth QoQ (YoY)4.97%
EPS Growth (5Y)21.23%
P/E Normalized (Annual)16.06x
ROA (Last FY)13.34%
Revenue Growth TTM (YoY)1.31%
EBITD / Share (TTM)$10.08
ROE (5Y Avg)27.67%
Operating Margin (TTM)32.64%
Cash Flow / Share (Annual)$4.99
P/B Ratio5.57x
P/B Ratio (Quarterly)4.97x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.04x
Net Interest Coverage (TTM)32.78x
ROA (TTM)14.63%
EPS Growth QoQ (YoY)-19.34%
EV / EBITDA (TTM)12.97x
EPS Incl Extra (Annual)$7.28
Current Ratio (Annual)1.54x
Quick Ratio (Quarterly)1.30x
3-Month Avg Trading Volume12.11M
52-Week Price Return55.73%
EV / Free Cash Flow (Annual)26.53x
P/E Incl Extra (TTM)16.06x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$10.48
P/S Ratio (Annual)4.51x
Asset Turnover (Annual)0.47x
52-Week High$125.14
Operating Margin (5Y Avg)24.53%
EPS Excl Extra (Annual)$7.28
CapEx CAGR (5Y)-1.47%
Tangible BV CAGR (5Y)19.33%
26-Week Price Return38.47%
Quick Ratio (Annual)1.30x
13-Week Price Return7.26%
Total Debt / Equity (Annual)0.94x
Current Ratio (Quarterly)1.54x
Enterprise Value$327,900.8
Revenue / Share Growth (5Y)9.68%
Asset Turnover (TTM)0.52x
Book Value / Share Growth (5Y)16.27%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.88x
Pretax Margin (Annual)32.41%
Cash / Share (Annual)$5.89
3-Month Return Std Dev24.70%
Gross Margin (5Y Avg)75.18%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)28.36%
ROE (Last FY)34.70%
Net Interest Coverage (Annual)12.35x
EPS Basic Excl Extra (Annual)$7.28
P/FCF (TTM)23.72x
Receivables Turnover (TTM)5.90x
EV / Free Cash Flow (TTM)26.53x
Total Debt / Equity (Quarterly)0.94x
EPS Incl Extra (TTM)$7.28
Receivables Turnover (Annual)5.90x
ROI (TTM)20.13%
Dividend Growth Rate (5Y)5.92%
P/S Ratio (TTM)4.51x
Pretax Margin (5Y Avg)24.57%
Revenue / Share (Annual)$25.93
Tangible BV / Share (Annual)$10.48
Forward P/E22.91x
Free OCF CAGR (5Y)16.24%
Price vs S&P 500 (52W)20.63%
P/E Ratio (TTM)16.06x
EPS Growth TTM (YoY)8.02%
Year-to-Date Return13.12%
5-Day Price Return-0.90%
EPS Normalized (Annual)$7.28
ROA (5Y Avg)10.79%
Net Profit Margin (Annual)28.08%
Month-to-Date Return-1.01%
Cash Flow / Share (TTM)$3.33
EBITD / Share (Annual)$9.88
EPS Growth (3Y)8.43%
Operating Margin (Annual)32.64%
LT Debt / Equity (Annual)0.89x
P/CF (TTM)17.80x
ROI (5Y Avg)15.23%
P/E Excl Extra (TTM)16.06x
LT Debt / Equity (Quarterly)0.89x
EPS Basic Excl Extra (TTM)$7.28
P/TBV (Quarterly)10.08x
Payout Ratio (Annual)44.79%
P/B Ratio (Annual)4.97x
Dividend / Share (TTM)$3.27
Inventory Turnover (TTM)2.18x
Pretax Margin (TTM)32.41%
Book Value / Share (Annual)$21.26
Price vs S&P 500 (13W)4.40%
Net Margin Growth (5Y)10.53%
Dividend Yield (TTM)2.79%
Beta0.27x
P/FCF (Annual)23.72x
Revenue / Share (TTM)$26.13
ROE (TTM)36.19%
52-Week Low$73.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.85
3.85
3.89
3.91
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share) | 1.40x | 69.14% | 72.55% | -8.08% | $47.99 |
About
Merck is a diversified pharmaceutical company with a leading immuno-oncology franchise anchored by Keytruda, a substantial vaccine business including Gardasil, and cardiometabolic disease treatments. The company also operates animal health segments globally, with 47% of revenue derived from US human pharmaceuticals and vaccines.